SAN DIEGO, March 10, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook at 12:30 p.m. PT on Wednesday, March 15, at the 29th Annual ROTH Conference (Newport Beach, California March 12 – 15). A webcast of the company’s presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Contact: Tony Ramos (858) 646-1127 Website: www.vical.com


SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges
Meta Expands AI Training With Employee Activity Tracking Tools
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries”
European Car Sales Surge in March as EV and Hybrid Demand Accelerates
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 



